Yazar "Aktepe, Oktay Halit" seçeneğine göre listele
Listeleniyor 1 - 4 / 4
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Efficacy analyses of axitinib and nivolumab in metastatic renal cell carcinoma after failure of targeted therapy: Which is better?(Zerbinis Publications, 2021) Aktepe, Oktay Halit; Ardic, Fadime Sinem; Yuce, Deniz; Guven, Deniz Can; Guner, Gurkan; Yildirim, Hasan Cagri; Kilickap, SaadettinPurpose: The objective of the present study was to compare the efficacy of axitinib and nivolumab in metastatic renal cell carcinoma (mRCC) previously treated with targeted therapy. Methods: A total of 79 patients were enrolled (39 patients in axitinib group, 40 patients in nivolumab group). Survival outcomes of patients, progression-free survival (PFS), and overall survival (OS) were estimated using the Kaplan-Meier method and compared with the log-rank test. The associations between potential prognostic variables and OS were evaluated in univariate and multivariate Cox regression analyses. Results: The median PFS and OS of all cohort were 8.1 and 36.6 months, respectively. Higher PFS and OS were evaluated in axitinib group than nivolumab group (PFS: 9.4 months vs 6.3 m2onths, p=0.386; OS: 38.2 months vs 36.6 months, p=0.671, respectively). Patients treated with axitinib had numerically higher objective response rate (ORR) and disease control rate (DCR) than those treated with nivolumab (ORR: 43.6% vs 27.6%, p=0.157, DCR: 74.4% vs 62.5%, p=0.157, respectively). Multivariate analysis revealed that the independent predictors of OS were higher tumor grade (hazard ratio [HR]: 6.178, p=0.004), worse response to axitinib and nivolumab (HR:4.902, p=0.011), the presence of lung metastasis (HR:15.637, p=0.002) and the presence of liver metastasis (HR:12.010, p=0.001). Conclusion: Comparable survival outcomes were detected in the axitinib and nivolumab groups. However, head to head comparisons are needed to highlight the relative efficacy of these therapies in mRCC.. © 2021 Zerbinis Publications. All rights reserved.Öğe EPİTELOİD KARSİNOMLU HASTADA CAMPYLOBACTER COLI ENFEKSİYONUNA BAĞLI GELİŞEN BAKTERİYEMİ: OLGU SUNUMU(2024) Şentürk, Ersin; Avcioğlu, Fatma; Aktepe, Oktay Halit; Behçet, Mustafa; Afşar, Yusuf; Kurtoğlu, MuhammetCampylobacter türleri akut bakteriyel gastroenterit etkenleri arasında yer almasına rağmen nadiren de olsa immünsüprese ve ileri yaş grubunda olan hastalarda invaziv hastalıklara neden olabilmektedir. Campylobacter; mikroaerofilik, nonfermentatif, Gram negatif bir bakteridir. Campylobacter türlerinin mikroaerofilik olması ve seçici besiyeri gereksinimi nedeniyle normal laboratuvar şartlarında üretilmesi zor gibi görülse de uygun şartlar sağlandığında bu mümkün olabilmektedir. Gelişen tanısal laboratuvar hizmetleri ile Campylobacter türlerinin tanısında gen bölgelerini hedefleyen moleküler tanı yöntemleri ortaya çıksa da halen altın standart yöntem bakterinin izolasyonudur. Bu olguda; yaklaşık dört ay önce epiteloid karsinom (kolon ve rektum) tanısı alan, sigmoid kolon-rektumu birlikte alınarak kolostomi yapılan, hastanemiz tıbbi onkoloji kliniğinde kemoterapi tedavisi gören, kan kültüründen Campylobacter coli izole edilen ve şifa ile tedavi edilerek taburcu olan 56 yaşında kadın bir hasta sunulmuştur.Öğe Incidentally discovered extrauterine migration of a Lippes loop: should we let it stay?(2024) Yaşar, Ayşenur Buz; Dağistan, Emine; Aktepe, Oktay HalitIntrauterine devices (IUDs), a form of long-acting reversible fertility control, are often preferred for preventing pregnancy. The Lippes loops, made of plastic, are inserted into the uterus via the cervix, fitting into the uterine cavity. The non- medicated (inert) structure of the loop allows for long-term IUD use. Uterine perforation and translocation of the IUD are the most threatening complications. In this case report, we present an asymptomatic 79-year-old woman with a forgotten IUD that migrated into the abdominal cavity and was discovered during her follow-up for lung cancerÖğe THSD7A expression: a novel immunohistochemical determinant in predicting overall survival of metastatic renal cell carcinoma treated with targeted therapy(Springer London Ltd, 2022) Aktepe, Oktay Halit; Gundogdu, Fatma; Kosemehmetoglu, Kemal; Yeter, Haci Hasan; Aksoy, Sercan; Guven, Deniz Can; Sahin, Taha KorayBackground The association of thrombospondin type 1 domain-containing 7A (THSD7A) expression, a novel angiogenesis-related marker, with survival outcomes of tumors including renal cell carcinoma (RCC) remains to be clarified. Therefore, we investigated the impact of THSD7A on outcomes of metastatic RCC (mRCC) patients treated with targeted therapy. Methods A total of 86 mRCC patients were included. The expression of THSD7A in nephrectomy material of the patients was assessed by immunohistochemistry and expression patterns were categorized into two groups: negative (no staining) and positive. Univariable and multivariable Cox regression models evaluated the impact of THSD7A expression on progression free survival (PFS) and overall survival (OS) of the patients. Results THSD7A expression was determined in 77.9% of the patients. Kaplan-Meier analyses showed that while the patients with THSD7A expression had significantly inferior OS times than those with negative THSD7A expression (19.9 months vs. 52.2 months, P = 0.024, respectively), there was no association between THSD7A expression and PFS. The univariate analyses demonstrated that the significant variables in predicting OS were presence of bone metastasis (P = 0.030), THSD7A expression (P = 0.028), and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) scoring system (P < 0.001). However, applying multivariate analyses, the independent variables in predicting OS were THSD7A expression (HR: 2.639, P = 0.037) and IMDC scoring system (P < 0.001). Conclusion We revealed that THSD7A expression was associated with OS of mRCC patients treated with targeted therapy. There might be an important link between THSD7A expression and resistance to targeted therapy.
